Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

4.1k

US$21.53

67.7% unterbewertet

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Daiichi Sankyo Company, Limited Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Daiichi Sankyo Company
Historische Aktienkurse
Aktueller Aktienkurs	JP¥18.36
52-Wochen-Hoch	JP¥29.15
52-Wochen-Tief	JP¥16.93
Beta	-0.30
1 Monat Veränderung	0.44%
3 Monate Veränderung	-15.97%
1 Jahr Veränderung	-22.92%
3 Jahre Veränderung	-42.84%
5 Jahre Veränderung	-39.43%
Veränderung seit IPO	164.81%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	DSKY.F	US Pharmaceuticals	US Markt
7D	3.9%	-1.0%	-0.6%
1Y	-22.9%	25.5%	21.7%

Rendite im Vergleich zur Industrie: DSKY.F unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 24.2% erzielte.

Rendite vs. Markt: DSKY.F hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 21.3 erzielte.

Preisvolatilität

Is DSKY.F's price volatile compared to industry and market?
DSKY.F volatility
DSKY.F Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.7%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: DSKY.F hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: DSKY.FDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1899	19,765	Hiroyuki Okuzawa	www.daiichisankyo.com

Daiichi Sankyo Company, Limited produziert und vertreibt pharmazeutische Produkte in Japan, Nordamerika, Europa und international. Das Unternehmen bietet Enhertu zur Behandlung von Patienten mit HER2-positivem und niedriggradigem Brustkrebs, HER2-positivem Adenokarzinom des Magens oder der gastroösophagealen Verbindungsstelle und HER2-positiven soliden Tumoren an; Turalio, ein oral zu verabreichendes kleines Molekül, das auf den Rezeptor des koloniestimulierenden Faktors 1, die proto-onkogene Rezeptor-Tyrosinkinase KIT und die FMS-ähnliche Tyrosinkinase 3 mit einer internen Tandem-Duplikationsmutation abzielt; Vanflyta, ein FLT3-Inhibitor zur Behandlung erwachsener Patienten mit akuter myeloischer Leukämie; und Injectafer, eine Eisencarboxymaltose-Injektion zur Behandlung von Eisenmangel. Darüber hinaus bietet das Unternehmen Liziana und Savaysa, direkte Faktor-Xa-Inhibitoren, die Blutdrucksenker Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar und Sevikar HCT, Nilemdo, eine orale Behandlung zur Senkung des Cholesterinspiegels, Nustendi, eine fest dosierte Kombinationstablette aus Bempedosäure und Ezetimib zur Senkung des Cholesterinspiegels, sowie Efient, ein Mittel gegen Blutplättchen.

Daiichi Sankyo Company, Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Daiichi Sankyo Company im Vergleich zum Marktanteil des Unternehmens?
DSKY.F grundlegende Statistiken
Marktanteil	US$33.27b
Gewinn(TTM)	US$1.93b
Umsatz(TTM)	US$12.99b

17.3x

Kurs-Gewinn-Verhältnis

2.6x

Kurs-Umsatz-Verhältnis

Ist DSKY.F zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DSKY.F Gewinn- und Verlustrechnung (TTM)
Einnahmen	JP¥2.05t
Kosten der Einnahmen	JP¥460.94b
Bruttogewinn	JP¥1.59t
Sonstige Ausgaben	JP¥1.29t
Gewinn	JP¥304.60b

Zuletzt gemeldete Gewinne

Dec 31, 2025

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	164.86
Bruttomarge	77.54%
Nettogewinnspanne	14.84%
Schulden/Eigenkapital-Verhältnis	17.6%

Wie hat sich DSKY.F auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.7%

Aktuelle Dividendenrendite

42%

Ausschüttungsquote

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/10 03:05
Aktienkurs zum Tagesende	2026/03/10 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, mit dem dieser Bericht erstellt wurde, sind auf unserer Github-Seite verfügbar. Außerdem bieten wir Anleitungen zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Daiichi Sankyo Company, Limited wird von 27 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Daiichi Sankyo Company (DSKY.F) Aktienübersicht

Belohnungen

Risikoanalyse

Looking to be second time lucky with a game-changing new product

Daiichi Sankyo Company, Limited Wettbewerber

Teva Pharmaceutical Industries

Royalty Pharma

Zoetis

Bristol-Myers Squibb

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

Recent updates

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Datroway Approves in Us for EGFRm Lung Cancer

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 17,000,000 shares, representing 0.91% for ¥50,000 million.

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited Provides Updated on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Daiichi Sankyo's Datopotamab Deruxtecan is Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd)

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer